Pozelimab/Cemdisiran
R3918-OT-2383
Phase 1 other active
Quick answer
Pozelimab/Cemdisiran for Sporadic Inclusion Body Myositis (sIBM) is a Phase 1 program (other) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Sporadic Inclusion Body Myositis (sIBM)
- Phase
- Phase 1
- Modality
- other
- Status
- active